NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders that will make a clinically meaningful difference in patients’ lives. NeuroDerm’s technology enables new routes of administration for existing drugs that overcome their current deficiencies and achieve enhanced clinical efficacy.
NeuroDerm Announces First Quarter 2015 Financial Results and Provides Corporate Update
Company to Host Conference Call and Webcast Today at 8:30 a.m. ET .”> Read More
NeuroDerm Announces Lifting of FDA Clinical Hold on ND0612, a Subcutaneously Delivered Levodopa/Carbidopa for the Treatment of Parkinson’s Disease
ND0612H and ND0612L U.S. Clinical Development Cleared to Proceed”> Read More
NeuroDerm Files Annual Report on Form 20-F for the Year Ended December 31, 2014
NeuroDerm Ltd. announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2014 with the U.S. Securities and Exchange Commission (“SEC”). ”> Read More